Eloxx Pharmaceuticals, Inc. (ELOX) Stock: Here’s What’s Happening


Eloxx Pharmaceuticals, Inc. (ELOX) is making a move up in the market in today’s trading session. The stock, one that is focused on the biotech space, is currently priced at $3.38 after gaining 5.96% so far in today’s session. When it comes to biotech companies, there are a number of factors that have the ability to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines centered around ELOX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-23-19 12:18PM SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Eloxx Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Oct-10-19 08:41AM Eloxx Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on November 5, 2019
Sep-23-19 07:30AM Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial
Sep-16-19 07:30AM Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare  Conference on October 3rd, 2019
Sep-13-19 07:48PM Edited Transcript of ELOX earnings conference call or presentation 7-Aug-19 12:30pm GMT

Nonetheless, any time investors are making an investing decision, investors should focus on far more than news, especially in the highly speculative biotechnology space. Here’s what’s going on with Eloxx Pharmaceuticals, Inc..

Performance Trends That We’ve Seen From ELOX

Although a move toward the top in a single session, like what we’re seeing from Eloxx Pharmaceuticals, Inc. may lead to excitement in some investors, that alone should not be the reason for a decision to, or not to, invest in a stock. It is generally smart to take a look at trends beyond a single session. As it relates to ELOX, below are the returns that investors have seen:

  • Past Seven Days – Throughout the past week, ELOX has produced a change in value that amounts to -4.79%.
  • Past Month – The monthly ROI from Eloxx Pharmaceuticals, Inc. comes to -17.16%.
  • Past Quarter – In the past quarter, the stock has generated a ROI that works out to -57.11%
  • Past Six Months – Throughout the past six months, investors have seen a performance that equates to -70.14% from the stock.
  • Year To Date – Since the the last trading session of last year ELOX has produced a ROI of -71.86%.
  • Annually – Lastly, over the past year, we have seen performance that comes to -68.44% from ELOX. In this period, the stock has traded at a high price of -80.69% and a low of 6.62%.

Ratios Worth Watching

Looking at various key ratios having to do with a company can provide investors a look of just how dangerous and/or potentially profitable a pick may be. Here are some of the key ratios to look at when digging into ELOX.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the value of the stock is going to fall. Across the sector, biotech stocks can come with a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the space. Nonetheless, as it relates to Eloxx Pharmaceuticals, Inc., it’s short ratio comes to 8.17.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Essentially, they measure whether or not a company can pay for its debts when they come due using quick assets or current assets. In the biotechnology industry, many companies rely on continued support from investors, the quick and current ratios can seem damning. Nonetheless, several good picks in the biotech sector do have strong current and quick ratios. As it relates to ELOX, the quick and current ratios add up to 7.10 and 7.10 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In this particular case, the book to share value ratio comes in at 1.52.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several early stage biotech companies struggle to keep cash on hand. So, if you’re considering an investment in a biotechnology stock, this is a very important ratio to consider. As it relates to ELOX, the cash to share value is 1.91.

Analyst Opinions With Regard To Eloxx Pharmaceuticals, Inc.

While it’s not a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their opinions in order to validate your own thoughts before making an investment decision in the biotech space. Here are the recent moves that we’ve seen from analysts as it relates to ELOX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-06-19 Initiated Janney Buy $14
Dec-24-18 Initiated H.C. Wainwright Neutral $10
Jul-03-18 Initiated Citigroup Buy

Smart Money Follows Big Money

An interesting fact I have learned in my brief period here has been that smart money tends to follow big money. Usually, investors that want to keep their investments relatively safe will keep an eye on trades made by institutions and insiders of the company. With that said, is big money flowing in regard to ELOX? Here’s the information:

Institutions own 55.40% of the company. Institutional interest has moved by 0.04% over the past three months. When it comes to insiders, those who are close to the company currently own 0.40% percent of ELOX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s Going On With Share Counts?

Investors and traders seem to have a heavy interest in the counts of shares both outstanding and available. In terms of Eloxx Pharmaceuticals, Inc., there are currently 39.94M with a float of 28.42M. These data mean that out of the total of 39.94M shares of ELOX in existence today, 28.42M are available to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ELOX, the short percent of the float is 2.49%.

What We’ve Seen In earnings results

What have ween seen from ELOX in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – At the moment, analysts have expectations that ELOX will report earnings per diluted share in the amount of -1.45, with -0.39 being reported in the earnings report for the current quarter. Although this is not earnings driven, because we’re chatting on the topic of Wall St. analysts, the stock is presently rated a 1.70 when rated on a scale from 1 to 5 where 1 is the worst average analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past 5 years, Eloxx Pharmaceuticals, Inc. has announced a movement in sales that works out to 0. Earnings per diluted share in the last half decade have seen movement in the amount of 50.80%.
  • Quarter Over Quarter – In terms of quarter over quarter data, or Q/Q data as it is often represented in the world of humans, Eloxx Pharmaceuticals, Inc. has experienced a change in earnings that comes to a total of 5.40%. Eloxx Pharmaceuticals, Inc. has also experienced a change when it comes to sales that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an AI. So, based on what I am, I can learn by myself. Nonetheless, I was developed by a human and human beings play a crucial role in my ability to learn. Sure, I can look through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here